Shares of General Electric Company (NYSE: GE) closed with gain of +0.13% to $7.58. Recent traded volume was 158,647,765 shares versus to it an average volume of 112,166,674 shares. The company holds 8973.88 million shares outstanding and market cap of 65.932B. The stock’s day range was recorded between a low of $7.26 and a high $7.74. The one year high of the company is $19.39 and the one year low is $7.26.
GE Healthcare recently reported new applications and smart devices built on Edison – a platform that assists accelerate the development and adoption of Artificial Intelligence (AI) technology and empower providers to deliver faster, more precise care. Edison is part of GE Healthcare’s $1B and growing Digital portfolio and will serve as a “digital thread” for its existing AI joint ventures and products. Clinical partners will use Edison to develop algorithms, and technology partners will work with GE Healthcare to bring the recent advancements in data processing to Edison applications and smart devices.
The healthcare AI market will reach $6.6B in 2021, and 39 percent of healthcare provider executives say that they’re investing in AI, machine learning and predictive analytics. Appreciating the technology’s potential, GE Healthcare is presenting the following Edison applications and Edison-powered devices at the 104th yearly meeting of the Radiological Society of North America (RSNA).
- AIRx* is an AI-based, automated workflow tool for MRI brain scanning designed to raise consistency and productivity. AIRxis designed to provide automated slice prescriptions to help reduce before redundant, manual steps. AIRx is intended to produce images that have less variability between technologists and between scans, to help lower the chances for a patient to be recalled Because of incorrect slice placement. An raise in consistency is particularly important when doing longitudinal assessments for diseases like Alzheimer’s and Multiple Sclerosis. AIRx features a pre-trained neural network model that leverages deep learning algorithms and anatomy recognition based on a database of over 36,000 images sourced from clinical studies and reference sites.*510(k) pending at FDA. Not accessible for sale.
- Critical Care Suite* onOptima XR240amx is designed to identify cases with the critical condition of pneumothorax at the point-of-care to enable prioritization of image review. Critical Care Suite will employ a suite of AI algorithms, such as pneumothorax detection, designed to identify this potentially life-threatening condition in chest X-Rays with high accuracy (>0.95 AUC). The AI algorithms are hosted on the mobile X-Ray system – a first of its kind AI-embedded imaging device – designed to share the output through an onscreen notification. When a pneumothorax condition is identified, the point-of-care notification alerts the clinical team, enabling prioritization of image review. The AI results are sent to PACS for review of the critical findings by a radiologist. *510(k) pending at FDA. Not accessible for sale.
- CT Smart Subscriptionprovides continuous access to the recent CT software, extending the lifecycle of the device and making it more valuable over time. Applications can be selected based on a hospital or health system’s exclusive needs, with options ranging from intracranial hemorrhage and stroke detection to routine dose reduction and optimization to cardiac function assessment.
- Automated Lesion Sectionation on LOGIQ™ E10 raises productivity through automation. Ultrasound users experience important ergonomic challenges Because of repetitive exam steps. Automated Lesion Sectionation assists eliminate the need for the user to measure lesions manually, by sectioning an identified breast, thyroid or liver lesion and automatically providing a trace of the lesion and corresponding area. This feature also assists ensure consistency among different users, or even the same user, for documentation and follow-ups.
“There’s a lot of hidden meaning in the deep data, but it takes a important sophistication to extract the value,” stated Dr. Rachael Callcut, a partner in the development of Critical Care Suite, Associate Professor of Surgery at UCSF, a surgeon at UCSF Health and Director of Data Science for the Center for Digital Health Innovation. “AI gives us an prospects to see patterns that we don’t see and change the way we care for patients, which can ultimately improve outcomes.”
(GE) is recorded at 0.54 and the relative strength index of the stock stands 26.68. The stock price is going above to its 52 week low with 0.66% and lagging behind from its 52 week high with -60.90%. A look on the firm performance, its monthly performance is -35.76% and a quarterly performance of -40.64%. The stock price is moving down from its 20 days moving average with -15.39% and isolated negatively from 50 days moving average with -31.16%.